This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace.
Analysis of top Seeking Alpha coverage: Regeneron
Today we will discuss an article on Regeneron (REGN) by DoctoRx, titled “Regeneron Falls On Q3 Report: Weighing The Pros And Cons.”
Regeneron has had a decent run this year, gaining more than 10%. More recently though the stock has seen a sharp pullback. REGN had climbed to above $500 in July this year. But then a spate of bad news pushed the stock lower. DoctoRx begins the article by talking about the negative news flow over the summer that pushed REGN lower. The author notes that he was expecting REGN to hold at around $450, but the stock fell through this level.
